Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Raksha Biovac is a veterinary combination vaccine developed by Indian Immunologicals Limited (IIL) for the simultaneous immunization of cattle and buffaloes against Foot-and-Mouth Disease (FMD) and Hemorrhagic Septicemia (HS). The vaccine is formulated as an oil-adjuvanted emulsion containing inactivated antigens of Foot-and-Mouth Disease Virus (FMDV) serotypes O, A, and Asia 1, along with inactivated *Pasteurella multocida*. It is designed to stimulate a protective humoral immune response against both viral and bacterial pathogens, thereby reducing the need for separate vaccinations and improving compliance in mass vaccination programs. The vaccine has been extensively utilized in India's national livestock health initiatives, including the Foot-and-Mouth Disease Control Programme (FMD-CP) and the Livestock Health Disease Control Program.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Raksha Biovac.